Obesity products projected to vary widely in acceptance | Healthcare Reflections Blogs
LinkedIn Login

Connect healthcare products, companies and hospitals with your LinkedIn network.

Facebook Login

Interact with your Facebook network around healthcare products, companies and hospitals.

Login With Facebook
MedicExchange Login

Enjoy Premium Access as a MedicExchange Member.

       Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

Facebook Twitter Linkedin
Facebook: MedicExchange
Twitter: MedicExchange

Obesity products projected to vary widely in acceptance

Healthcare Blogs - Healthcare Reflections Blogs

Further to our post yesterday, reflecting the changing landscape of obesity treatment options, there will be a wide range of the growth rates for options over the ten year period from 2009-2019.  In descending order, below, are listed the obesity treatment options in terms of sales revenue annual growth rates:

  • Gastric Emptying Devices
  • Appetite Suppression Devices
  • Malabsorption Devices
  • Combination Drugs
  • Satiety Drugs
  • Artificial Fullness Devices
  • App Suppression Drugs
  • Restrictive Devices
  • Malabsorption Drugs

On the low end, malabsorption drugs will demonstrate an actual net decline over the forecast period while, on the high end, gastric emptying devices, which are 1-2 years away from approval, will go from zero to a nearly $200 million annual market by 2019.


For further information, see Report #S835, ” Products, Technologies and Markets Worldwide for the Clinical Management of Obesity, 2011-2019.”

Read More: http://feedproxy.google.com/~r/AdvancedMedicalTechnologies/~3/effYt1MO8Tw/